Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials
Fanyue Meng(Tianjin University), Fengcai Zhu(Jiangsu Provincial Center for Disease Control and Prevention), Siyue Jia(Jiangsu Provincial Center for Disease Control and Prevention), Jiu-Qin Wan(Yangzhou University), Mingwei Wei(Jiangsu Provincial Center for Disease Control and Prevention), Bopei Cui(China National Biotechnology (China)), Zhilong Ma(Tongji University), Fan Gao(Soochow University), Xuewen Wang(Shenzhen University Health Science Center), Zhiming Wu(Yangzhou University), Jing Zhang(Children's Hospital of Fudan University), Jingxin Li(Beijing Tongren Hospital), Xiànghóng Wú(Shandong University), Zhongkui Zhu, Xiling Guo(Jiangsu Provincial Center for Disease Control and Prevention), Hailin Peng(Nantong University), Jialu Zhang(National Institutes for Food and Drug Control), Hongxing Pan(Jiangsu Provincial Center for Disease Control and Prevention)
Cited by 36
Related Papers
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
|The Lancet Infectious Diseases|2020|1.5k
Hand, foot, and mouth disease in China, 2008–12: an epidemiological study
|The Lancet Infectious Diseases|2014|977
Co-infection with respiratory pathogens among COVID-2019 cases
|Virus Research|2020|637